Across TCGA pan-cancer cohorts, RNASEH2B Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RNASEH2B data layer compared with 22 for mass-spec protein and 7 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher RNASEH2B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RNASEH2B expression acts as an unfavorable survival marker.
COAD and UCEC are the cancer types where RNASEH2B Mutation most reproducibly stratifies survival.